Related Experiment Videos

The clinical implication of inhibiting platelet activation on chronic renal allograft dysfunction: a prospective

Y Zhang1, H T Zong, C C Yang

  • 1Urology Department, Beijing Chao Yang Hospital Capital Medical University, Beijing, China. doctorzhy@126.com

Transplantation Proceedings
|September 14, 2011
PubMed

Insights

Inhibiting platelet activation effectively and safely treats chronic renal allograft dysfunction (CRAD) by improving kidney microcirculation and delaying fibrosis. This approach stabilizes serum creatinine and enhances glomerular filtration rate in transplant recipients.

Area of Science:

  • Nephrology
  • Transplantation Immunology
  • Vascular Biology

Background:

  • Chronic renal allograft dysfunction (CRAD) is a major cause of long-term kidney transplant failure.
  • CRAD is characterized by rising serum creatinine, worsening proteinuria, and declining glomerular filtration rate (GFR).
  • Strategies to delay or reverse CRAD and improve graft survival are critical in transplantation.

Purpose of the Study:

  • To evaluate the therapeutic efficacy and safety of inhibiting platelet activation in living related donor renal transplant recipients with CRAD.
  • To assess the impact of platelet activation inhibition on key biomarkers and kidney function.

Main Methods:

  • A prospective cohort study was conducted.
  • Measured platelet activation markers (CD61, CD63, PAC-1), PDGF-BB, and TGF-β(1) in peripheral blood.
  • Correlated these markers with kidney function, platelet counts, and immunosuppressant levels.

Main Results:

  • Inhibition of platelet activation significantly decreased expression of CD61, CD63, PAC-1, PDGF-BB, and TGF-β(1).
  • Serum creatinine and urea nitrogen levels remained stable, unlike the control group.
  • Glomerular filtration rate (GFR) improved significantly post-treatment.

Conclusions:

  • Inhibiting platelet activation is an effective and safe treatment for CRAD.
  • The mechanism likely involves improved kidney microcirculation and reduced TGF-β expression, thereby delaying fibrosis.
  • This strategy offers a promising approach to enhance long-term kidney transplant outcomes.
Abstract

Related Concept Videos

Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...